Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Riluzole Clear all
Terminated Phase 1 Interventional

Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

NCT01018836
View directory record Official record
Conditions
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
riluzole, whole-brain radiation therapy
Drug · Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 19, 2026, 2:27 AM EDT
Terminated Phase 2 Interventional Results available

Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)

NCT03679975
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Riluzole Oral Soluble film (ROSF) 50 mg
Drug
Lead sponsor
Aquestive Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 19, 2026, 2:27 AM EDT
Recruiting Phase 2 Interventional

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

NCT07142291
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg)
Drug
Lead sponsor
PhenoNet, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 19, 2026, 2:27 AM EDT
Completed Phase 2 Interventional

Memantine Therapy in Amyotrophic Lateral Sclerosis

NCT01020331
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Memantine
Drug
Lead sponsor
Phoenix Neurological Associates, LTD
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Oct 19, 2026, 2:27 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

NCT03127267
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Masitinib (6.0), Riluzole, Placebo, Masitinib (4.5)
Drug
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 81 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 19, 2026, 2:27 AM EDT
Active, not recruiting Phase 1 Interventional

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

NCT01303341
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Melanoma, Refractory Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Riluzole, Sorafenib Tosylate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 19, 2026, 2:27 AM EDT
Active, not recruiting No phase listed Observational

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

NCT06529146
View directory record Official record
Conditions
Spinocerebellar Ataxias
Interventions
BHV-4157
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 19, 2026, 2:27 AM EDT
Terminated Phase 2 Interventional Results available

Riluzole to Treat Depression in Bipolar Disorder

NCT00054704
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Riluzole, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 19, 2026, 2:27 AM EDT
Recruiting Phase 2 Interventional

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

NCT07447050
View directory record Official record
Conditions
Breast Cancer, Sarcoma, Gastric (Stomach) Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Genitourinary Cancer, Gynecologic Cancer
Interventions
Riluzole, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 19, 2026, 2:27 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Riluzole Augmentation Pilot in Depression (RAPID) Trial

NCT01703039
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Riluzole, Sertraline, placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 19, 2026, 2:27 AM EDT
Terminated Phase 1 Interventional

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

NCT00667901
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
riluzole, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 19, 2026, 2:27 AM EDT
Terminated Phase 2 Interventional Results available

Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder

NCT00805493
View directory record Official record
Conditions
Bipolar Disorder, Anxiety Disorders, Bipolar Affective Disorder, Bipolar Depression
Interventions
Riluzole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
9 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 19, 2026, 2:27 AM EDT
Withdrawn Phase 2 Interventional

Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis

NCT03457753
View directory record Official record
Conditions
ALS
Interventions
Riluzole Oral Soluble Film
Drug
Lead sponsor
Aquestive Therapeutics
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 19, 2026, 2:27 AM EDT
Recruiting Early Phase 1 Interventional

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

NCT06552260
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, Brain Tumor
Interventions
Troriluzole
Drug
Lead sponsor
Ugonma Chukwueke
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 19, 2026, 2:27 AM EDT
Completed Not applicable Interventional

Treatment of Refractory Schizophrenia With Riluzole

NCT00375050
View directory record Official record
Conditions
Schizophrenia, Schizoaffective
Interventions
Riluzole, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 19, 2026, 2:27 AM EDT
Recruiting Phase 2 Interventional

RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring

NCT05292209
View directory record Official record
Conditions
Atrial Fibrillation Paroxysmal
Interventions
Riluzole 50 MG
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 19, 2026, 2:27 AM EDT
Completed Phase 1 Interventional

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

NCT03520517
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease, Lou-Gehrigs Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
BHV-0223
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Lincoln, Nebraska • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 19, 2026, 2:27 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

NCT00818389
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Lithium Carbonate, Riluzole, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 19, 2026, 2:27 AM EDT
Completed Phase 4 Interventional Results available

Riluzole in Fragile X Syndrome

NCT00895752
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Riluzole
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 19, 2026, 2:27 AM EDT
Terminated No phase listed Observational

A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder

NCT01019967
View directory record Official record
Conditions
Childhood Obsessive-Compulsive Disorder, Autism Spectrum Disorders
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 19, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT02238626
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo (for MN-166), MN-166, riluzole
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 19, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00866840
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
riluzole
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 19, 2026, 2:27 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants

NCT07618715
View directory record Official record
Conditions
Healthy Male and Female Subjects
Interventions
Y-4 tablet, Pregabalin capsule, Riluzole tablet
Drug
Lead sponsor
Neurodawn Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 19, 2026, 2:27 AM EDT
Recruiting Phase 2 Interventional

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

NCT06580002
View directory record Official record
Conditions
Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Genitourinary Cancer, Gynecologic Cancer, Urinary Bladder Cancer, Leukemia, Lymphoid Leukemia, Myeloma Multiple, Prostate Cancer, Pancreas Cancer, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Brain Cancer, Melanoma, Mycosis Fungoides, Kidney Cancer
Interventions
Riluzole, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 19, 2026, 2:27 AM EDT